Pandion is focused on developing therapeutics for a wide range of autoimmune and inflammatory indications.

We are advancing a pipeline of precision immune modulators targeting critical immune nodes, including PT101, our lead drug candidate. Using our TALON™ platform, we are also developing novel PD-1 agonists and other programs for systemic and tissue-targeted immune control. Our tissue-specific programs target the gut, liver, skin, kidneys, and pancreas.


Our discovery efforts are focused on expanding our library of tether and effector modules. We have work ongoing for autoimmune diseases of the skin, kidney and pancreas. We are also developing a CD39 effector designed to manipulate the inflammatory microenvironment.

Back to Top